Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?

Main Article Content

Nabil Ismaili *
Sanaa Elmajjaoui
Youssef Bensouda
Rhizlane Belbaraka
Halima Abahssain
Wafa Allam
Zouhour Fadoukhair
Mohamed Mesmoudi
Rachid Tanz
Tarik Mahfoud
Abdelhamid Elomrani
Mouna Khouchani
Yassir Sbitti
Noureddine Benjaafar
Hassan Errihani
Ali Tahri
(*) Corresponding Author:
Nabil Ismaili | ismailinabil@yahoo.fr

Abstract

Bladder cancer is the fourth most common cancer for men and the eighth most common cancer for women. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting the treatment is based on cisplatin chemotherapy regimens type MVAC, MVAC-HD or gemcitabine plus cisplatin. The standard treatment of muscle invasive operable bladder cancer (T2–T4) used widely was radical cystectomy with pelvic lymph nodes dissection; the anatomical extent of pelvic lymphadenectomy has not accurately been defined so far. However, in the last decade, the treatment of tumors was improved by the introduction of chemotherapy as part of the management of the disease. Neoadjuvant chemotherapy should be considered at first, as standard treatment of choice, before local treatment for patients with good performance status (0–1) and good renal function–glomerular filtration rate (GFR) >60 mL/min. For patients treated with primary surgery, adjuvant chemotherapy is a valuable option in the case of lymph nodes involvement. This brief review would provide the evidence of the role of neoadjuvant chemotherapy in the management of operable muscle invasive (T2–T4) bladder cancer.

Downloads month by month

Downloads

Download data is not yet available.

Article Details